anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Sepsis-induced lung injury is a common critical condition in clinical practice, characterized by the accumulation of peroxides and inflammatory damage caused by excessive macrophage activation. Currently, effective treatments for sepsis-induced lung injury are lacking. Short-chain fatty acid receptor FFAR2 serves as an anti-inflammatory biomarker, but its role and mechanism in sepsis-induced lung injury remain unclear. To elucidate the influence and mechanism of FFAR2 on macrophage lipid peroxidation levels in sepsis-induced lung injury, this study conducted bioinformatics analysis and cellular experiments using the THP-1 macrophage cell line. By dual luciferase reporter and chromatin immunoprecipitation-quantitative PCR assays, it is confirmed that the transcription factor VDR upregulates FFAR2 expression in macrophages by binding to the promoter region -1695 ∼ 1525, thereby increasing the expression of iron death negative regulatory molecules and lowering macrophage lipid peroxidation levels. Moreover, both in vitro using THP-1 cells and bone marrow-derived macrophages (BMDMs) and in vivo using an LPS-induced septic mice model experiments revealed that activating the VDR/FFAR2 axis could reduce inflammation-induced macrophage lipid peroxide accumulation and alleviate lung injury in septic mice. This finding highlights the potential of FFAR2 as an immunotherapeutic target for mitigating sepsis-related lung injury.
Chronic pain, which affects more than one-third of the world's population, represents one of the greatest medical challenges of the 21st century, yet its effective management remains sub-optimal. The 'gold standard' for the treatment of moderate to severe pain consists of opioid ligands, such as morphine and fentanyl, that target the µ-opioid receptor (MOP). Paradoxically, these opioids also cause serious side effects, including constipation, respiratory depression, tolerance, and addiction. In addition, the development of opioid-use disorders, such as opioid diversion, misuse, and abuse, has led to the current opioid crisis, with dramatic increases in addiction, overdoses, and ultimately deaths. As pain is a complex, multidimensional experience involving a variety of pathways and mediators, dual or multitarget ligands that can bind to more than one receptor and exert complementary analgesic effects, represent a promising avenue for pain relief. Indeed, unlike monomodal therapeutic approaches, the modulation of several endogenous nociceptive systems can often result in an additive or even synergistic effect, thereby improving the analgesic-to-side-effect ratio. Here, we provide a comprehensive overview of research efforts towards the development of dual- or multi-targeting opioid/nonopioid hybrid ligands for effective and safer pain management. We reflect on the underpinning discovery rationale by discussing the design, medicinal chemistry, and in vivo pharmacological effects of multitarget antinociceptive compounds.
Periodontitis is featured as the periodontium's pathologic destruction caused by the host's overwhelmed inflammation. Omentin-1 has been reported to be aberrantly downregulated in patients with periodontitis, but the specific regulation of Omentin-1 during the pathogenesis of periodontitis remains unclear. In this study, human periodontal ligament stem cells (hPDLSCs) were stimulated by lipopolysaccharide (LPS) from Porphyromonas gingivalis to establish an in vitro inflammatory periodontitis model. hPDLSCs were treated with recombinant human Omentin-1 (250, 500 and 750 ng/mL) for 3 h before LPS stimulation. Results revealed that Omentin-1 significantly inhibited LPS-induced inflammation in hPDLSCs through reducing the production of proinflammatory cytokines (tumor necrosis factor-α (TNF-α), interleukin (IL)-1β and IL-6) and downregulating the expression of Cox2 and iNOS. Meanwhile, Omentin-1 significantly enhanced alkaline phosphatase (ALP) activity and Alizarin red-stained area, accompanied by increasing expression osteogenic markers BMP2, OCN and Runx2, confirming that Omentin-1 restores osteogenic differentiation in LPS-induced hPDLSCs. In addition, the conditioned medium (CM) from LPS-induced hPDLSCs was harvested to culture macrophages, which resulted in macrophage polarization towards M1, while CM from Omentin-1-treated hPDLSCs reduced M1 macrophages polarization and elevated M2 polarization. Furthermore, Omentin-1 also inhibited LPS-triggered endoplasmic reticulum (ER) stress in hPDLSCs, and additional treatment of the ER stress activator tunicamycin (TM) partially reversed the functions of Omentin-1 on inflammation, osteogenic differentiation and macrophages polarization. In summary, Omentin-1 exerted a protective role against periodontitis through inhibiting inflammation and enhancing osteogenic differentiation of hPDLSCs, providing a novelty treatment option for periodontitis.
The trial is designed to investigative the risk and clinical benefit of chemotherapy and intensive endocrine therapy for Luminal B1 early-staged breast cancer. In this trial the investigators will randomly assign 200 primary breast cancer patients to receive four cycles of epirubicin and cyclophosphamide (EC) followed by four cycles of docetaxel(T), or four cycles of docetaxel and cyclophosphamide (TC) followed by intensive endocrine therapy (Goserelin acetate+Tamoxifen/Letrozole for young patients) . Patients with HER-2 positive was excluded. The patient's conditions will be assessed before, and after every four cycles of adjuvant chemotherapy to determine if there is any progression of the disease. The patient's conditions will be assessed every three months when they received the intensive endocrine therapy (Goserelin acetate+Tamoxifen for young patients/Letrozole for postmenopausal patients). Patients will be followed up for DFS and OS in different regiments, the secondary endpoint is to assess the expression of female hormone levels. The correlation of the expression of female hormone levels with the clinical outcomes, so that the investigators could optimize adjuvant treatment regiment with luminal B1 breast cancer.
A dietary supplement is provided whereby the daily administration of materials derived from the Acacia plants is provided orally to humans for the purpose of producing or maintaining weight loss as well as improving a person's physical performance and increasing the person's lean muscle mass. The Acacia materials include these portions of the plant that are normally considered waste or inedible, such as leaves, bark, and roots. The materials can be administered in their natural form or as extracts, and can be administered in various ways including capsules and tablets. The Acacia material may also be used as a tea. For weight loss and weight control, the materials may also be administered concurrently with caloric restriction or in the absence of caloric restriction. The materials may also be administered for the purpose of increasing muscle mass concurrently with a high protein diet as well as an exercise program.
Ifosfamide for Injection can cause encephalopathy which may be fatal. Signs and symptoms may include confusion, somnolence, coma, hallucination, blurred vision, psychotic behavior, extrapyramidal symptoms, urinary incontinence, and seizures.

Risk factors include high ifosfamide dosage, hypoalbuminemia, impaired renal function, poor performance status, bulky abdominal-pelvic disease, nephrotoxic treatments including cisplatin, CNS active drugs, or alcohol use.

Signs and symptoms may occur or recur within hours to days after administration of Ifosfamide for Injection. Continue supportive care until complete resolution of CNS signs and symptoms.

Monitor for signs and symptoms of encephalopathy during and after Ifosfamide for Injection treatment. Dose interruption or permanent discontinuation may be required based on individual safety and tolerability. Consider methylene blue for treatment of encephalopathy.
Sensors may be attached to a patient's skin near a joint. An image of the joint and sensors may be captured and a bone centerline may be determined based on the image. A first set of measurements, which may include varus and valgus information, may be captured at the sensors, and may be captured while the patient is in a first position. The first set of measurements may then be transmitted to a handheld device. A second set of measurements corresponding to a second position of the patient may be captured at the sensors. The second set of measurements may also include varus and valgus information and may also be transmitted to the handheld device. A difference between the first set of measurements and the second set of measurements, including the difference between the varus and valgus measurements, may be determined.
Cholestatic liver diseases, such as primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC), lead to inflammation and severe hepatic damage with limited therapeutic options. This study assessed the efficacy of the inverse RORγt agonist, GSK805, both in vitro using the hepatic stellate cell-line LX-2 and in vivo using male bile duct-ligated BALB/c mice. In vitro, 0.3 μM GSK805 reduced alpha-smooth muscle actin expression in LX-2 cells. In vivo, GSK805 significantly decreased IL-23R, TNF-α, and IFN-γ expression in cholestatic liver. Despite high concentrations of GSK805 in the liver, no significant reduction in fibrosis was noticed. GSK805 significantly increased aspartate aminotransferase and alanine aminotransferase activity in the blood, while levels of glutamate dehydrogenase, alkaline phosphatase, and bilirubin were not substantially increased. Importantly, GSK805 did neither increase an animal distress score nor substantially reduce body weight, burrowing activity, or nesting behavior. These results suggest that a high liver concentration of GSK805 is achieved by daily oral administration and that this drug modulates inflammation in cholestatic mice without impairing animal well-being.
Patients taking the maximum recommended NEUPRO dose for early-stage Parkinson's disease had a higher incidence (2%) of substantial weight gain (more than 10% of baseline weight) than patients taking placebo (0%). In advanced-stage Parkinson's disease, the incidence of weight gain more than 10% of baseline weight was 9% in NEUPRO-treated patients (for the maximum recommended dose) and 1% in placebo-treated patients. This weight gain was frequently associated with the development of peripheral edema in patients with Parkinson's disease, suggesting that NEUPRO may cause fluid retention in some Parkinson's patients. In patients taking the maximum recommended NEUPRO dose, the incidence of peripheral edema was 3% for NEUPRO and 2% for placebo in early-stage Parkinson's disease and 9% for NEUPRO and 1% for placebo in advanced-stage Parkinson's disease. These treatment differences increased further with treatment at NEUPRO dosing above the maximum recommended doses. Monitor for weight gain and fluid retention when treating patients with concomitant illnesses such as congestive heart failure or renal insufficiency.
FIELD: veterinary science. SUBSTANCE: method involves dissolving a pyrethroid in dimethylsulfoxide or ethyl alcohol and pouring the prepared solution in polyethylene glycol or vaseline oil. Mixture is stirred for 3-60 min at the room temperature, kept for 1-24 h and stirred again for 3-30 min. The prepared preparation is used for animal protection against ectoparasites: mites, lice, fleas and Trichodectes. EFFECT: enhanced effectiveness of preparation, prolonged fitness time, broadened pattern of using. 6 cl, 1 tbl, 1 ex
PURPOSE:To provide a supergualin preparation containing supergualins and simple lipids exhibiting oily, semisolid or solid state at normal temperature and useful as a carcinostatic agent, immunosuppressor, etc. CONSTITUTION:The objective agent can be prepared by compounding (A) supergualin, its derivative or analogous compound (called as supergualins) with (B) simple lipids which are oily, semisolid or solid at normal temperature (e.g., an ester of a 4-32C fatty acid and a 1-32C mono- or polyalcohol) and, as necessary, (C) an additive and forming to a drug preparation by conventional process. The amount of the simple lipids is >=0.1 pts.wt. per 1 pt.wt. of the supergualins. The contents of supergualins, simple lipids and other additive are 5-60wt.%, 90-30wt.% and 0-70wt.% based on the whole drug preparation, respectively. A drug for oral administration such as tablet, hard capsule or granule as well as a drug for injection can be prepared from the supergualins in addition to a drug for injection.
Cell therapy based on mesenchymal stem cells (MSCs) alleviate muscle atrophy caused by diabetes and aging; however, the impact of human umbilical cord mesenchymal stem cells on muscle atrophy following nerve injury and the underlying mechanisms remain unclear. In this study, we evaluated the therapeutic efficacy of human umbilical cord MSCs (hucMSCs) and hucMSC-derived exosomes (hucMSC-EXOs) for muscle atrophy following nerve injury and identified the underlying molecular mechanisms. Sciatic nerve crush injury in rats and the induction of myotubes in L6 cells were used to determine the ameliorating effect of hucMSCs and hucMSC-EXOs on muscle atrophy. Q-PCR and Western blot analyses were used to measure the expression of muscle-specific ubiquitin ligases Fbxo32 (Atrogin1, MAFbx) and Trim63 (MuRF-1). Dual-luciferase reporter gene experiments were conducted to validate the direct binding of miRNAs to their target genes. Local injection of hucMSCs and hucMSC-EXOs mitigated atrophy in the rat gastrocnemius muscle following sciatic nerve crush injury. In vitro, hucMSC-EXOs alleviated atrophy in L6 myotubes. Mechanistic analysis indicated the upregulation of miR-23b-3p levels in L6 myotubes following hucMSC-EXOs treatment. MiR-23b-3p significantly inhibited the expression of its target genes, Fbxo32 and Trim63, and suppressed myotube atrophy. Notably, an miR-23b-3p inhibitor reversed the inhibitory effect of miR-23b-3p on myotube atrophy in vitro. These results suggest that hucMSCs and their exosomes alleviate muscle atrophy following nerve injury. MiR-23b-3p in exosomes secreted by hucMSCs contributes to this mechanism by inhibiting the muscle-specific ubiquitination ligases Fbxo32 and Trim63.
For topical ophthalmic use only. Not for injection. This preparation may cause CNS disturbances. This is especially true in younger age groups, but may occur at any age, especially with the stronger solutions. Infants are especially prone to CNS and cardiopulmonary side effects from cyclopentolate. To minimize absorption, use only 1 drop of 0.5% Cyclopentolate Hydrochloride Ophthalmic Solution USP per eye, followed by pressure applied over the nasolacrimal sac for two to three minutes. Observe infants closely for at least 30 minutes following instillation.

Mydriatics may produce a transient elevation of intraocular pressure.
While fecal microbiota transplantation (FMT) has been shown to be effective in reversing gut dysbiosis, we lack an understanding of the fundamental processes underlying microbial engraftment in the mammalian gut. Here, we explored a murine gut colonization model leveraging natural inter-individual variations in gut microbiomes to elucidate the spatiotemporal dynamics of FMT. We identified a natural "super-donor" consortium that robustly engrafts into diverse recipients and resists reciprocal colonization. Temporal profiling of the gut microbiome showed an ordered succession of rapid engraftment by early colonizers within 72 h, followed by a slower emergence of late colonizers over 15-30 days. Moreover, engraftment was localized to distinct compartments of the gastrointestinal tract in a species-specific manner. Spatial metagenomic characterization suggested engraftment was mediated by simultaneous transfer of spatially co-localizing species from the super-donor consortia. These results offer a mechanism of super-donor colonization by which nutritional niches are expanded in a spatiotemporally dependent manner. A record of this paper's transparent peer review process is included in the supplemental information.
Six months after the inception of the trial, elementary schools (and their teachers) in the control condition will receive an unguided version of the intervention, supplemented by an online peer support group. As the children of the control group will by then be in high school with different teachers, we will provide them with a toolkit of 10 mental health activities that they can practice alone, in addition of support via video-conference, phone or email if they require help practicing the activities from a member of the research team. As in the intervention group, we will provide support by licensed psychologists to any children who report high levels of psychological distress and orient children to appropriate services if needed.
BACKGROUND: Effective cancer pain management is essential for improving the quality of life of patients. However, the use of analgesics is often suboptimal due to various patient-related barriers. This study aims to explore the perceptions, knowledge, and attitudes toward analgesic use among cancer patients in Oman, which may influence their pain management strategies.
METHODS: In a cross-sectional study, we assessed 68 cancer patients undergoing pain management at an inpatient cancer clinic of a tertiary hospital in Oman from a pool of 154 eligible participants. The Barriers Questionnaire (BQ) and the Patient Pain Questionnaire (PPQ), both Arabic versions, were administered to evaluate the patients' barriers to cancer pain management. The study period and the criteria for patient selection are specified.
RESULTS: With a participation rate of 44.2% and a female-to-male ratio of 2.28:1, the mean score on the BQ was 2.52 (SD 0.84), indicating a moderate level of perceived barriers. Patients' scores suggested notable barriers, with older patients exhibiting reluctance toward analgesics for fear of masking symptoms and female patients expressing greater concerns about developing drug tolerance.
CONCLUSION: The findings highlight significant attitudinal barriers to effective cancer pain management in Oman, notably a prevalent fear of medication tolerance. The study stresses on the need for targeted patient education and the correction of misconceptions. It also points to the influence of cultural and religious beliefs on patient responses, advocating for the implementation of culturally sensitive, evidence-based pain management guidelines, and the support of multidisciplinary palliative care teams.
The invention discloses a preparation method of Bulbophyllurn radiatum Lindl. submicron powder. The preparation method comprises the following steps of 1, pretreatment: taking a fresh or dried Bulbophyllurn radiatum Lindl. medicinal material, removing impurities, cleaning the Bulbophyllurn radiatum Lindl. medicinal material by water and cutting the cleaned Bulbophyllurn radiatum Lindl. medicinal material into slices, sections or shredded Bulbophyllurn radiatum Lindl., 2, low-temperature refrigeration, 3, low-temperature crushing for preparation of coarse powder of 40-100 meshes, 4, low-temperature vacuum microwave drying, 5, low-temperature air-flow crushing until granularity is less than 200 meshes, and 6, low-temperature resonance ultramicro-pulverization until granularity is less than 300 meshes, and split charging and packaging so that the Bulbophyllurn radiatum Lindl. submicron powder finished product is obtained. The preparation method is economic and environmentally friendly, effectively utilizes the Bulbophyllurn radiatum Lindl. medicinal material and improves medicinal effects.
NEW MATERIAL:The compound of formulaI(R is methyl or phenyl). EXAMPLE:Penicillanic acid-1,1-dioxide (5-methyl-2-oxo-1,3-dioxolen-4-yl)-methyl ester. USE:A beta-lactamase inhibiting agent exhibiting excellent absorbability or bioavailability in living body by oral administration. PROCESS:The compound of formulaIcan be prepared by reacting the penicillanic acid-1,1-dioxide of formula II or its salt with the compound of formula III (X is halogen) in an inert organic solvent such as DMF preferably in the presence of a base (e.g. NaHCO3) at -40-+80 deg.C, preferably -10 deg.C- room temperature. The compound of formula III used as a starting raw material is a novel compound, and is obtained by the reaction of the compound of formula IV with a halogenating agent (e.g. N-bromosuccinimide).
The present invention discloses a tigecycline composition for injection. The composition comprises active components such as tigecycline and a proppant, and further comprises a stabilizer. The invention further discloses a stable pharmaceutically-acceptable reconstruction liquid after tigecycline lyophilizing. The tigecycline composition has good reconstituting property, and can be dissolved without vigorous shaking, such that foams produced due to vigorous shaking can be avoided. According to the tigecycline composition for inection, and the reconstruction liquid after tigecycline composition dilution, experiment results show that oxidative degradation and epimer generation are significantly reduced, and tigecycline preparation stability is enhanced. Compared with the existing clinically used composition, the composition of the present invention has the following effects that: treatment effects of tigecycline can be increased, potential safety hazards caused by lactose can be avoided, stability during production, storage and clinical use processes is easily achieved, and clinical use requirements can be met.
Mobile application has become an important and necessary element in nursing education and clinical nursing practices, and its use has gradually increased. Neonatal intensive care units (NICUs) are areas where complex and quality health care is provided for newborns. The development of the nursing process, especially in the neonatal intensive care unit, may shorten the duration of the care that should be provided to newborns. New ways such as mobile applications can be sought to assist in the realization of the nursing process and to strengthen the diagnostic perception of neonatal nurses. This study is a randomized controlled experimental study designed to determine the effect of the mobile application developed for the care of sick newborns in the Neonatal Intensive Care Unit on nurses' perception of nursing diagnoses and care that cannot be met, and to measure the usability of the mobile application. A total of 69 nurses working in the neonatal intensive care unit in turkey will constitute the universe of the research. In this study, participants will be selected for experimental and control groups using a stratified random sampling method (the stratification criteria will be based on the institutions where the nurses work). The sample will be calculated as experimental group: 27 control group: 27 in total. Samples from the identified substrates will be selected using the random numbers table.

In this study, Nurse Descriptive Characteristics Form; Nursing Diagnosis Perception Scale ; Questionnaire for Determining "missed nursing care" in the Neonatal Intensive Care Unit created by the researcher ; System Usability Scale will be used. For the missed nursing care nursing care determination questionnaire, expert opinion was taken and applied to the pilot group, and its content validity was checked.